|Day Low/High||6.91 / 7.29|
|52 Wk Low/High||3.10 / 12.80|
Resubmission of the REMOXY NDA On-Track for Q1 2018
Peer-reviewed Publication Supports On-Going Clinical Development of PTI-125
PTI-125 Is Well-Tolerated in First-in-human Clinical Study
Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.
Provides Funding for FENROCK™, an Abuse-deterrent Pain Patch
Clinical Study Initiation Is Expected Shortly, with Funding by NIH
NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate
PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease
Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017
- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -
Here's a technical look at how to trade some of the most active stocks on the market right now.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
Company Will Host Conference Call Monday, September 26th at 9:00am EDT
No Change to September 25th PDUFA Date
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.